TO study the efficacy of Haridradi Leha in the management of Tamaka Shwasa with respect to Bronchial Asthma.

Efficacy of Haridradi Leha in the management of Tamaka Shwasa with respect to Bronchial Asthma- An open labelled randomized controlled clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054886

Enrollment

Registered

2023-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Haridradi Avaleha: Dose:10 gm thrice a day Anupana: warm water Route:Oral Bhaisjya Kala:Empty Stomach Duration:6 weeks Control Intervention1: HARIDRADI AVALEHA: Dose: 10gm Thrice a day

Eligibility

Inclusion criteria

Inclusion criteria: Patient with chronicity of Tamaka Shwasa less than 10 yrs. Patients present with classical signs and symptoms of Tamaka Shwasa such as ShwasaKrichchhata (Dyspnoea), Ghurghurukama (Wheezing sound),Kasa (Cough),Asamyakanidra (Disturbed sleep),Kantodhwamsa (Hoarseness of voice) Pinasa (Rhinitis),Shleshma Vimokshante Muhurtam Sukham (After expectoration patient feels better) ParshvaAvgrihyate (Chest tightness),Aasinolabhatesaukhyama (Comfortable in sitting position) PEF: =50-100%

Exclusion criteria

Exclusion criteria: Patients suffering from Diabetes mellitus. Patients of complicated liver diseases, Renal diseases and cardiac diseases. Patients with poorly controlled hypertension. Patients of Cor pulmonale, Cardiac Asthma and severe exacerbation. Patient with acute and chronic infections like Pneumonitis, Tuberculosis, HIV etc. Patients with major systemic illness RA, SLE and severe metabolic disorders like Gout. Any acute systemic disease or Infection, with post covid lung disease/complication. Pregnant and lactating mothers. Any malignancy. Acute & serious conditions require immediate intervention will be excluded

Design outcomes

Primary

Measure	Time frame
Results will be assessed on the basis of gradation of clinical features of Tamaka Shwasa like ? ShwasaKrichchhata (Dyspnoea) ? Ghurghurukama (Wheezing sound) ? Kasa (Cough) ? Asamyakanidra (Disturbed sleep) ? Kantodhwamsa (Hoarseness ofvoice) ? Pinasa (Rhinitis) ?ShleshmaVimokshanteMuhurtamSukham (After expectoration patient feels better) ? ParshvaAvgrihyate (Chest tightnes) ? Aasinolabhatesaukhyama (Comfortable in sitting position)Timepoint: 2 weeks of completion of clinical trial	—

Measure

Time frame

Results will be assessed on the basis of gradation of clinical features of Tamaka Shwasa like ? ShwasaKrichchhata (Dyspnoea) ? Ghurghurukama (Wheezing sound) ? Kasa (Cough) ? Asamyakanidra (Disturbed sleep) ? Kantodhwamsa (Hoarseness ofvoice) ? Pinasa (Rhinitis) ?ShleshmaVimokshanteMuhurtamSukham (After expectoration patient feels better) ? ParshvaAvgrihyate (Chest tightnes) ? Aasinolabhatesaukhyama (Comfortable in sitting position)Timepoint: 2 weeks of completion of clinical trial

—

Secondary

Measure	Time frame
Peak flow meter reading to access improvement of lung functionsTimepoint: 42 days	—

Countries

India

Contacts

Public ContactDr Anamika Soni

Government Akhandanand Ayurved College and Hospital

ayursoni@yahoo.com9269533108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026